Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 3;13(11):1610.
doi: 10.3390/biom13111610.

Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors

Affiliations

Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors

Veronica Salmaso et al. Biomolecules. .

Abstract

Adenosine receptors are largely distributed in our organism and are promising therapeutic targets for the treatment of many pathologies. In this perspective, investigating the structural features of the ligands leading to affinity and/or selectivity is of great interest. In this work, we have focused on a small series of pyrazolo-triazolo-pyrimidine antagonists substituted in positions 2, 5, and N8, where bulky acyl moieties at the N5 position and small alkyl groups at the N8 position are associated with affinity and selectivity at the A3 adenosine receptor even if a good affinity toward the A2B adenosine receptor has also been observed. Conversely, a free amino function at the 5 position induces high affinity at the A2A and A1 receptors with selectivity vs. the A3 subtype. A molecular modeling study suggests that differences in affinity toward A1, A2A, and A3 receptors could be ascribed to two residues: one in the EL2, E168 in human A2A/E172 in human A1, that is occupied by the hydrophobic residue V169 in the human A3 receptor; and the other in TM6, occupied by H250/H251 in human A2A and A1 receptors and by a less bulky S247 in the A3 receptor. In the end, these findings could help to design new subtype-selective adenosine receptor ligands.

Keywords: GPCR; adenosine receptor; antagonists; molecular modeling; pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Synthesis of compounds 17. Reagents and Conditions: i: RCOCl, TEA, THF, reflux, 18 h.
Figure 1
Figure 1
Docking pose of compound 11 (grey) at hA1 (pink, (A)), hA2A (cyan, (B)), hA3 (orange, (C)), and hA2B (blue, (D)) AR structures. The following receptor 3D structures were employed: experimental X-ray for hA1 (PDB IDs: 5UEN) and hA2A ARs (PDB IDs: 4EIY), homology models for hA2B and hA3 ARs (built on hA2A and hA1, respectively). A ZM-241385-like docking pose is displayed here.
Figure 2
Figure 2
Docking pose of compound 4 (yellow) at hA1 (pink, (A)), hA2A (cyan, (B)), hA3 (orange, (C)), and hA2B (blue, (D)) AR structures. The following receptor 3D structures were employed: experimental X-ray for hA1 (PDB IDs: 5UEN) and hA2A ARs (PDB IDs: 4EIY), homology models for hA2B and hA3 ARs (built on hA2A and hA1, respectively). Structures were refined with induced-fit docking of compound 4 before re-docking it rigidly.

Similar articles

References

    1. Borea P.A., Gessi S., Merighi S., Vincenzi F., Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol. Rev. 2018;98:1591–1625. doi: 10.1152/physrev.00049.2017. - DOI - PubMed
    1. Burnstock G. A basis for distinguishing two types of purinergic receptor. In: Bolis L., Straub R.W., editors. Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Raven Press; New York, NY, USA: 1978. pp. 107–118.
    1. IJzerman A.P., Jacobson K.A., Müller C.E., Cronstein B.N., Cunha R.A. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. Pharmacol. Rev. 2022;74:340–372. doi: 10.1124/pharmrev.121.000445. - DOI - PMC - PubMed
    1. Vincenzi F., Pasquini S., Contri C., Cappello M., Nigro M., Travagli A., Merighi S., Gessi S., Borea P.A., Varani K. Pharmacology of Adenosine Receptors: Recent Advancements. Biomolecules. 2023;13:1387. doi: 10.3390/biom13091387. - DOI - PMC - PubMed
    1. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 2006;5:247–264. doi: 10.1038/nrd1983. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources